Emit Imaging was founded with the core mission of revolutionizing molecular tissue imaging and digital histology. The company focuses on developing and providing advanced cryo-fluorescence imaging technology, which enables high-resolution, high-sensitivity 3D imaging of tissues. Their flagship product, Xerra™, is a preclinical imaging tool designed to monitor drug pharmacokinetics and pharmacodynamics (PK/PD) and protein expression in whole animals. Emit Imaging primarily serves the biological and drug research markets, offering both instrumentation and imaging services.

Notable figures associated with Emit Imaging include leading experts in molecular imaging and digital histology. The company has attracted significant interest from investors focused on cutting-edge biomedical technologies. Key achievements include the successful development and commercialization of the Xerra™ platform, which has been widely adopted in preclinical research settings. Emit Imaging's impact is evident in its contribution to advancing drug discovery and biological research through innovative imaging solutions.